最新医学別冊　新しい診断と治療のABC6/消化器1　消化性潰瘍　改訂第2版

出版社： 最新医学社
発行日： 2012-12-25
分野： 臨床医学：一般  >  雑誌
ISSN： 03708241
雑誌名：
特集： 消化性潰瘍　改訂第2版
電子書籍版： 2012-12-25 （改訂第2版）
書籍・雑誌
≪全国送料無料でお届け≫
品切れ

5,500 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

4,400 円(税込)

購入する

目次

  • 最新医学別冊　新しい診断と治療のABC6/消化器1　消化性潰瘍　改訂第2版

    ―目次―

    特集　消化性潰瘍　改訂第2版

    第１章　概論・疫学
    　総論 　
    　疫学 　

    第２章　病理・病態生理
    　病理　
    　病態生理
    　　１．胃酸分泌機構 　
    　　２．胃粘膜防御機構 　
    　病因
    　　１．Helicobacter pylori 　
    　　２．非ステロイド性抗炎症薬(NSAIDs) 　
    　　３．低用量アスピリン　
    　　４．その他の病因 　

    第３章　診断
    　X線所見 　
    　内視鏡所見 　
    　超音波所見 　
    　胃癌との鑑別診断　

    第４章　管理・治療
    　管理・患者指導 　
    　薬物療法・選択基準 　
    　治療薬剤
    　　１．PPI 　
    　　２．Ｈ2ブロッカー 　
    　　３．H. pylori陽性潰瘍 　
    　　４．非ステロイド性抗炎症薬由来潰瘍 　
    　　５．低用量アスピリン由来潰瘍　１．病態?治療 　
    　内視鏡的治療（止血療法） 　
    　外科療法 　

    第５章　ガイドライン
    　消化性潰瘍診療ガイドライン 　

    第６章　診療のトピックス
    　Cox2阻害剤使用に当たってのピットホールとは？ 　
    　非ステロイド性抗炎症薬（低用量アスピリンを含む）由来の
    　　小腸病変に対する治療 　
    　消化性潰瘍治療薬の医療経済による評価 　
    　消化性潰瘍治療薬の副作用 　
    　防御因子増強薬はどのようなケースに使用するのか？

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1章 概論・疫学

P.25 掲載の参考文献
1) Warren J R et al:Unidentified curved bacilli on gastric epithelium in active gastritis (letter). Lancet 1:1273-1275, 1983.
 
2) Asaka M, et al:Current topics in the treatment of peptic ulcer Intern Med 39:339-342, 2000
PubMed
3) Nishikawa K, et al:Non-Helicobacter pylori and non-NSAID peptic ulcer disease in Japanese population. Eur J Gastroenterol Hepatol 12:635-640, 2000.
PubMed
P.31 掲載の参考文献
1) Kato I, et al:A prospective study of gastric and duodenal ulcer and its relation to smoking, alcohol, and diet Am J Epidemiol 135 (5):521-530, 1992.
 
2) 厚生労働省患者調査, 2008.
 
3) Take S, et al:The effect of eradicating Helicobacter pylori on the development of gastric cancer in patients with peptic ulcer disease. Am J Gastroenterol 100 (5):1037-1042, 2005.
PubMed
4) Uemura N, et al Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 345 (11):784-789, 2001.
PubMed
5) Hansson L E, et al:The risk of stomach cancer in patients with gastric or duodenalulcer disease. N Engl J Med 335 (4):242-249, 1996.
 
6) Risch HA, et al:ABO blood group, Helicobacter pylori seropositivity, and risk of pancreatic cancer:a case control study. J Nat Cancer Inst 102 (7):502-505, 2010
PubMed
7) Correa P, et al:The relationship between gastric cancer frequency and the ratio of gastric to duodenal ulcer. Aliment Pharmacol Ther 9 (Suppl 2):13-19 1995.
 
8) Azuma T:Helicobacter pylori CagA protein variation associated with gastric cancer in Asia. J Gastroenterol 39 (2):97-103, 2004.
 
9) Watanabe Y, et al:Epidemiological study of peptic ulcer disease among Japanese and Koreans in Japan. J Clin Gastroenterol 15 (1):68-74, 1992.
PubMed
10) Blaser M J:Age at establishment of Hellcobacter pylori infection and gastric carcinoma, gastric ulcer, and duodenal ulcer risk. Cancer Res 55 (3):562-565, 1995.
 
11) Kobayashi T, et al:Trends in the incidence of gastric cancer in Japan and their associations with Helicobacter pylori infection and gastric mucosal atrophy. Gastric Cancer 7 (4):233-239, 2004.
PubMed
12) 厚生労働省人口動態統計, 2011.
 

第2章 病理・病態生理

P.40 掲載の参考文献
1) Allen A, et al:Gastroduodenal mucosal protection. Physiol Rev 73:823-857, 1993.
PubMed
2) Morris G P, et al:The roles of ethanol and of acid in the production of gastric mucosal erosions in rats. Virchows Arch B Cell Pathol Incl Mol Pathol 38:23-38, 1981.
PubMed
3) Wallace J L:Increased resistance of the rat gastric mucosa to hemorrhagic damage after exposure to an irritant. Role of the "mucoid cap" and prostaglandin synthesis. Gastroenterology 94:22-32, 1988.
 
4) Wallace J L:Extracellular mucus and repair of superficial mucosal injury by restitution. Methods Find Exp Clin Pharmacol 11 (Suppl 1):27-33, 1989.
PubMed
5) Ota H, et al:Aberrant expression of TFF1, TFF2, and PDXI and their diagnostic value in lobular endocervical glandular hyperplasia. Am J Clin Pathol 135:253-261, 2011.
 
6) Ikeno T, et al:Helicobacter pylori-induced chronic active gastritis, intestinal metaplasia, and gastric ulcer in Mongolian gerbils. Am J Pathol 154:951-960, 1999.
PubMed
7) Suzuki K, et al:Trefoil factor 2 in gland mucous cell mucin in the mucous gel covering normal or damaged gastric mucosa using the Mongolian gerbil model. Scand J Gastroenterol 41:1390-1397, 2006.
PubMed
8) Wright N A, et al:Epidermal growth factor (EGF/URO) induces expression of regulatory peptides in damaged human gastrointestinal tissues. J Pathol 162:279-284, 1990.
PubMed
9) Podolsky D K:Mucosal immunity and inflammation. V. Innate mechanisms of mucosal defense and repair:the best offense is a good defense. Am J Physiol 277:G495-499, 1999,
PubMed
10) Podolsky D K:Mechanisms of regulatory peptide action in the gastrointestinal tract:trefoil peptides. J Gastroenterol 35 (Suppl 12):69-74, 2000.
 
11) 杉山 敦:実験胃潰瘍治癒過程の粘液組織化学的検討. 信州医誌 38:363-379, 1990.
 
12) Nozaki K, et al:A molecular signature of gastric metaplasia arising in response to acute parietal cell loss. Gastroenterology 134:511-522, 2008.
PubMed
13) 船津隆:健常胃粘膜および胃潰瘍再生粘膜の走査電子顕微鏡学的検討. 日消誌80:1-8, 1983.
 
P.51 掲載の参考文献
1) Debas H T:Peripheral regulation of gastric acid secretion of acid secretion. In:Physiology of Gastrointestinal Tract, 2nd ed, Vol. 2 (Johnson L R, ed), p931-945. Raven Press, New York, USA, 1987.
 
2) Tache Y, et al:Role of brainstem TRH/TRH-R1 receptors in the vagal gastric cholinergic responses to various stimuli including sham feeding. Auton Neurosci 125:42-52, 2006.
PubMed
3) Richardson C T, et al:Studies of the role of cephalic-vagal stimulation in the acid secretory response to eating in normal human subjects. J Clin invest 60:435-441, 1977.
PubMed
4) Tache Y:Central nervous system regulation of acid secretion. In:Physiology of Gastrointestinal Tract, 2nd ed, Vol 2 (Johnson LR, ed), p911-930. Raven Press, New York, USA, 1987.
 
5) Leonard A, et al:M3-subtype muscarinic receptor that controls intracellular calcium release and inositol phosphate accumulation in gastric parietal cell. Biochem Pharmacol 42:839-845, 1991.
PubMed
6) Schubert M L, et al:Functionally distinct muscarinic receptors on gastric somatostatin cells. Am J physiol Gastrointest Liver Physiol 258:G982-987, 1990.
 
7) Schubert M L, et al:Pepton stimulates gastrin secretion from the stomach by activating bombesin/GRP and cholinergic neurons. Am J physiol Gastrointest Liver Physiol 262:G685-G689, 1992.
 
8) Sandvik A K, et al:PACAP stimulates gastric acid secretion in the rant by inducing histamine release. Am J physiol Gastrointest Liver Physiol 281:G997-G1003, 2001.
 
9) Schubert M L, et al:Gastrin secretion induced by distention is regulated by cholinergic and vasoactive intestinal peptide neurons in rats. Gastroenterology 104:834-839, 1992.
 
10) Lichtenberger L M, et al:Importance of amino acid uptake and decarboxylation in gastrin release from isolated G cells. Nature 296:698-700, 1982.
 
11) Code C:Histamine and gastric secretion. In:Histamine (Wolstenholme G, et al, eds), p189-219. Little, Brown and Co, 1956.
 
12) Soll A H:Secretagogue stimulation of[14C] aminopyrine accumulation by isolated canine parietalcell. Am J Physiol 238:G366-G375, 1980
 
13) Ganz I, et al:Molecular cloning of a gene encoding the histamine H2-receptor. Proc Natl Acad Sci USA 488:429, 1991.
 
14) Kajimura M, et al:The muscarinic receptor gene expressed in rabbit parietal cells is the M3 suntype. Gastroenterology 103:807, 1992.
 
15) Kopin A S, et al:Expression cloning and characterization of the canine parietal cell gastrin receptor. Proc Natl Acad Sci USA 89:3605-3609, 1992.
PubMed
16) Sachs G, et al:A non-electrogenic H+pump in plasma membranes of hog stomach. J Biol Chem 251:7690-7698, 1976.
 
17) Hanzel D, et al:The secretion-stimulated 80K phosphoprotein of parietal cells is ezrin, and has properties of a membrane cytoskeletal linker in the induced apical microvilli. EMBO J 10:2363-2373, 1991.
PubMed
18) Asano S, et al:Molecular and cellular regulation of the gastric proton pump. Bio Pharm Bul 27:1-12, 2004.
 
19) Kopic S, et al:Revisiting the parietal cell. Am J Physiol Cell Physiol 298:C1-C10, 2010.
PubMed
20) Schubert M L:Regulation of gastric acid secretion. Physiology of Gastrointestinal Tract, fifth ed, Vol 2, p1281-1308. Elsevier BV, Amsterdam, Netherlands, 2012.
 
P.61 掲載の参考文献
1) Kubota S, et al:Quantitative determination of gland mucous cells-type mucin using a monoclonal antibody, HIK1083:its patho-physiological changes in human gastric juice. Clin Chim Acta 377:261-267, 2007.
 
2) Allen A, et al:Gastroduodenal mucus bicarbonate barrier:protection against acid and pepsin. Am J physiol Cell Physiol 288:C1-19, 2005.
PubMed
3) Atuma C, et al:The adherent gastrointestinal mucus gel layer:thickness and physical state in vivo. Am J physiol Gastrointest Liver Physiol 280:G922-929, 2001.
 
4) Chu S, et al:Dynamic regulation of gastric surface pH by luminal pH. J Clin Invest 103:605-612, 1999.
PubMed
5) Akiba Y, et al:Luminal chemosensing and upper gastrointestinal mucosal defenses. Am J Clin Nutrition 90:826S-831S, 2009.
 
6) Thim L, et al:Effect of trefoil factors on the viscoelastic properties of mucus gels. Eur J Clin Invest 32:519-527, 2002.
PubMed
7) May F E, et al:The human two domain trefoil protein, TFF2, is glycosylated in vivo in the stomach. Gut 46:454-459, 2000.
PubMed
8) Tanaka K-I, et al:Genetic evidence for a protective role of heat shock factor I against irritant-induced gastric lesions Mol Pharmacol 71:985-993, 2007.
 
9) Barker N et al:Lgr5 (+ve) stem cells drive self-renewal in the stomach and build long-lived gastric units in vitro Cell stem cell 6:25-36, 2010.
PubMed
10) Rokitansky C:A manual of pathological anatomy, translated by Swaine, WE, Vol. 2, pp40-43. Blanchard and Lea Philadephia, 1855.
 
11) Cushing H:Peptic Ulcer and the interbrain. Surg Gynecol Obstet 55:1-34, 1932.
 
12) Reilly J:Hemorrhagies, l0sions vasculaires et lymphatiques du tube digestif. CR Soc Biol 116:24-27, 1934.
 
13) Selye H:A syndrome by diverse nocuous agents. Nature 138:32, 1936.
 
14) French J D, et al:Gastrointestinal hemorrhage and ulceration associated with intracranial lesions. Surgery 32:395-407, 1952.
PubMed
15) 山口與市, 他:胃潰瘍と自律神経-Reilly現象の立場から-. 最新医 14:662-670, 1959.
 
16) 松尾裕:消化管における自律神経と消化管ホルモンとの関係. 自律神経 12:208, 1975,
 
17) 土屋雅春, 他:ラット胃粘膜微小循環の自律神経統御について. 日消誌 78:1000-1014, 1981.
 
18) Nakamura M, et al:Muscarinic acetylcholine receptors in rat gastric mucosa-a radioautographic study using a potent muscarinic antagonist, 3H-pirenzepine. Histochemistry 83:479-487, 1985.
PubMed
19) 関根一郎, 他:ストレスによる出血性胃炎と胃壁内カテコ-ルアミン. Ther Res 2:907-910, 1985.
Medical*Online
20) Cook D J, et al:The attributable mortality and length of intensive care unit stay of clinically important gastrointestinal bleeding in critically ill patients. Crit Care 5:368-375, 2001.
PubMed
21) Lundberg J M, et al:Occurrence of vasoactiveintestinal polypeptide (VIP)-like immunoreactivity in certain cholinergic neurons of the cat:evidence from combined immunohistochemistry and acetylcholineesterase staining. Neuroscience 4:1539-1559, 1979.
 
22) Nakamura M, et al:Autoradiographic demonstration of gastrin-releasing peptide-binding sites in the rat gastric mucosa. Gastroenterology 94:968-976, 1988.
PubMed
23) Edwall B, et al:Neuropeptide Y (NPY) and sympathetic control of blood flow in oral mucosa and dental pulp in the cat. Acta Physiol Scand 125:253-264, 1985.
PubMed
24) Furness J B, et al:Choline acetyltransferase and peptide immunoreactivity of submucous neurons in the small intestine of the guinea pig. Cell Tissue Res 237:328-336, 1984.
 
25) Chen R Y Z, et al:Role of calcitonin generelated peptidein capsaicin-induced gastric submucosal arteriolar dilation. Am J Physiol 262:H1350-H1355, 1992.
 
26) Foster E R, et al:The role of calcitonin gene-related peptide in gastric mucosal protectoin in the rat. Exp Physiol 76:623-626, 1991.
 
27) Holzer P, et al:Calcitonin gene-related peptide (CGRP) causes nitric oxide dependent and independent hyperemia in the rat stomach. Gastroenterology 104:A103, 1993.
 
28) Nakamura M, et al:Binding sites for CGRP in regenerated gastric mucosa. J Clin Gastroenterol 17 (Suppl 1):S46-52, 1993.
 
29) Seifert H, et al:Receptors for calcitonin gene-related peptide:binding to exocrine pancreas mediates biologicl actions. Am J Physiol 249:G147-G151, 1985.
 
30) Akiba Y, et al:Acid-sensing pathways in rat gastrointestinal mucosa. J Gastroenterol 37 (Suppl. XIV):133-138, 2002.
 
31) Peskar B M:Neural aspects of prostaglandin involvement in gastric mucosal defense. J Physiol Pharmacol 52:555-568, 2001.
PubMed
32) Blackler R, et al:Gastrointestinal-sparing effects of novel NSAIDs in rats with compromised mucosal defence. PLoS one 7:e35196, 2012.
PubMed
33) Wallace J L:Hydrogen sulfide:a rescue molecule for mucosal defence and repair. Digestive diseases and sciences 57:1432-1434, 2012.
PubMed
P.69 掲載の参考文献
1) 日本消化器病学会編:消化性潰瘍診療ガイドライン, 2009.
 
2) 日本ヘリコバクター学会編. H. pylori感染の診断と治療のガイドライン 2009 改訂版. 2009.
 
3) Fujisawa T, et al:Changes in seroepidemiological pattern of Helicobacter pylori and hepatitis A virus over the last 20 years in Japan. Am J Gastroenterol 94:2094-2099, 1999.
PubMed
4) Shimoyama T, et al:ABC screening for gastric cancer is not applicable in a Japanese population with high prevalence of atrophic gastritis. Gastric Cancer 15:331-334, 2012.
 
5) Shimoyama T, et al:High prevalence of the cagA-Positive Helicobacter pylori strains in Japanese asymptomatic patients and gastric cancer patients. Scand J Gastroenterol 32:465-468, 1997.
PubMed
6) 畠山昌則:ヘリコバクター・ピロリがんタンパク質CagA研究の新たな展開. 日消誌 108:1505-1513, 2011.
Medical*Online
7) Shimoyama T, et al:Evaluation of Helicobacter pylori VacA genotype in Japanese patients with gastric cancer. J Clin Pathol 51:299-301, 1998.
PubMed
8) Sakamoto C, et al:Case-control study on the association of upper gastrointestinal bleeding and nonsteroidal anti-inflammatory drugs in Japan. Eur J Clin Pharmacol 62:765-772, 2006.
PubMed
P.76 掲載の参考文献
1) Sandler R S, et al:A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 348 (10):883-890, 2003.
PubMed
2) Rothwell P M, et al:Long-term effect of aspirin on colorectal cancer incidence and mortality:20-year follow-up of five randomized trials. Lancet 376 (9754):1741-1750, 2010.
PubMed
3) Huang J Q, et al:Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in pepticulcer disease:a meta-analysis. Lancet 359 (9300):14-22, 2002.
 
4) 塩川優一, 他:非ステロイド性抗炎症剤による上部消化管障害に関する疫学研究. リウマチ31 (1):96-111, 1991.
 
5) Schoen R T, et al Mechanisms of nonsteroidal anti-inflammatory drug-inducedgastric damage. Am J Med 86 (4):449-458, 1989.
 
6) Rostom A, et al:Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev 4:CD002296, 2002.
PubMed
7) Hiraishi H, et al:Frequency of nonsteroidal anti-inflammatory drug-associated ulcers. Clin J Gastroenterol 5 (3):171-176, 2012
PubMed
8) Wolfe M M, et al Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 340 (24):1888-1899, 1999.
PubMed
9) Wallace J L:NSAID gastropathy and enteropathy:distinct pathogenesis likely necessitates distinct prevention strategy. Br J Pharmacol 165 (1):67-74, 2012.
 
10) Takeuchi K Pathogenesis of NSAID-induced gastric damage:Importance of cyclooxygenase inhibition and gastric hypermotility. World gastroenterol 18 (18):2147-2160, 2012.
PubMed
11) 科学的根拠(evidence)に基づく胃潰瘍診療ガイドラインの策定に関する研究班:EBMに基づく胃潰瘍診療ガイドライン第2版. pp101-110. じほう東京, 2007.
 
12) 小林壮光, 他NSAID胃粘膜障害の成因 直接的な傷害作用. 日臨65 (10) 1803-1806, 2007.
 
13) Robert A:Cytoprotection by prostaglandins. Gastroenterology 77 (4 Pt 1):761-767, 1979.
 
14) Wallace J L Prostaglandins, NSAIDs, and gastrlc mucosal protectlon:why doesn't the stomach digest itself? Physiol Rev 88 (4):1547-1565, 2008.
 
15) Sugimoto Y, et al:Prostaglandm E receptors. Biol Chem 282 (15):11613-11617, 2007.
 
16) Fu S, et al:Increased expression and cellular localization of inducible nitric oxide synthase and cyclooxygenase 2 in Helicobacter pylori gastritis. Gastroenterology 116 (6):1319-1329, 1999.
PubMed
17) Robert A, et al:Mild irritants prevent gastric necrosis through "adaptive cytoprotection"mediated by prostaglandi
 
18) Mizuno H, et al:Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology 112 (2):387-397, 1997.
PubMed
19) Wallace J L, et al:NSAID-induced gastric damage in rats:requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology 119 (3):706-714, 2000.
PubMed
20) Langenbach R, et al:Prostaglandin synthase I gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration Cell 83 (3):483-492, 1995.
PubMed
21) Hiraishi H et al:Involvement of oxldative stress in the pathogenesis of NSAID-induced gastric mucosal damage. J Gastroenterol 35 (7):567-569, 2000.
PubMed
22) Floruccl S, et al:The emerging roles of hydrogen sulfide in the gastrointestinal tract and liver. Gastroenterology 131 (1):259-271, 2006.
PubMed
P.82 掲載の参考文献
1) 三宅一昌, 他:抗血栓薬による粘膜傷害の病態. 血栓と循環 18:170-175, 2010.
Medical*Online
2) 大島忠之, 他:低用量アスピリンと従来型NSAIDの胃粘膜傷害機序, Helicobacter Res 13:92-97, 2009.
 
3) Derry S, et al:Risk of gastrointestined haemorrhage with long term use of aspirin:meta-analysis. BMJ 321:1183-1187, 2000.
PubMed
4) McQuaid K R et al:Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med 119:624-638, 2006.
PubMed
5) Hallas J, et al:Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding:population based case-control study. Br Med J 333:726-730, 2006.
 
6)Sakamoto C, et al:Case-control study on the association of upper gastrointestinal bleeding and nonsteroidal anti-inflammatory drugs in Japan. Eur J Clin Pharmacol 62:765-772,2006.
PubMed
7)Lanas A,et al:Nitrovasodilators low-dose aspirin other nonsteroidal antiinflammatory drugs and the risk of upper gastrointestinal bleeding N Engl J Med 343:834-839,2000.
PubMed
8)Ibanez L,et al:Upper gastrointestinal bleeding associated with antiplatelet drugs.Aliment Pharmacol Ther 23:235-242,2006.
PubMed
9)Lanas A,et al:Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin.Aliment Pharmacol Ther 16:779-786,2002.
PubMed
10)Yeomans N D, et al:Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther 22:795-801,2005.
PubMed
11) Nema H,et al:Endoscopic survey of low-dose-aspirin-induced gastroduodenal mucosal injuries in patients with ischemic heart disease.J Gastroenterol Hepatol 23(Suppl 2):S234-236,2008.
 
12) Shiotani A, et al:Upper gastrointestinal ulcer in Japanese patients taking low-dose aspirin.J Gastroenterol 44:126-131,2009.
PubMed
13) Tamura I, et al:Low-dose aspirin-induced gastroduodenal mucosal injury in Japanese patients with arteriosclerotic disease.Intern Med 49:2537-2545,2010.
PubMed
14) Kawai T, et al:Impact of upper gastrointestinal lesions in patients on low-dose aspirin therapy:preliminary study.J Gastroenterol Hepatol 25 (Suppl 1):S23-30,2010.
PubMed
15)Tamura A et al:Prevalence and independent factors for gastroduodenal ulcers/erosions in asymptomatic patients taking lowdose aspirin and gastroprotective agents:the OITA-GF study. Q J Med 104:133-139,2011.
 
P.91 掲載の参考文献
1) EBMに基づく胃潰瘍診療ガイドラインp4-6. じほう, 東京, 2008.
 
2) XIA HH-X, et al:Clinical and endoscopic characteristics of non-Helicobacter pylori, non-NSAID duodenal ulcers:a long-term prospective study. Aliment Pharmacol Ther 15:1875-1882, 2001.
 
3) Goenka M K, et al:Helicobacter pylori negative, non-steroidal anti-inflammatory drug-negative peptuc ulcers in India. Indian J Gastroenterol 30:33-37, 2011.
PubMed
4) Chan H L, et al:Is non-Helicobacter pylori, non-NSAID peptic ulcer a common cause of upper Gl bleeding? A prospective study of 977 patients. Gastrointest Endosc 53:438-442, 2001.
 
5) 加藤元嗣, 他:胃十二指腸潰瘍. 消化器内視鏡 24 (4):514-518, 2012.
 
6) 日本消化器病学会編:消化性潰瘍診療ガイドライン, 南江堂, 東京, 2009.
 
7) Conn H O, et al:Corticosteroids and peptic ulcer:meta-analysis of adverse events during steroid therapy. J Intern Med 236:619-632, 1994.
PubMed
8) Luu J C, et al:Clopidogrel delays gastriculcer healing in rats. Eur J Pharmacol 695:112-119, 2012.
 
9) 今井正之, 他:Zollinger-Ellison症候群患者(10人)におけるパリエット錠の臨床評価. Ther Res 26 (2):1287-1308, 2005.
 
10) Kanno T, et:Peptic ulcers after the Great East earthquake and tsunami:possible existence of psychosocial stress ulcers in humans. J Gastroenterol Published online (doi:10.1007/soo535-012-0681-1), 2012.
 

第3章 診断

P.102 掲載の参考文献
1) 日本消化器がん検診学会胃X線撮影法標準化委員会編:新・胃X線撮影法 (間接・直接) ガイドライン. メディカルレビュー社, 東京, 2005.
 
2) 日本消化器がん検診学会胃がん検診精度管理委員会編:新・胃X線撮影法ガイドライン 改訂版 (2011年). 医学書院東京, 2011.
 
3) 中島滋美, 他:新ガイドラインによる胃部X線検診の問題指摘とHelicobacter pylori感染を考慮した胃癌検診の提案. 日消がん検診誌 45 (5):534, 2007.
 
4) 中島滋美, 他:過伸展で腹臥位二重造影を行うべきか?仰臥位での前壁描出法の検討. 日消がん検診誌 48 (6):704, 2010.
 
5) 中島滋美:バリウム胃X線検査におけるHelicobacter pylori感染診断. Helicobacter Res 16:478-486, 2012.
Medical*Online
6) 中島滋美, 他:Helicobacter pylori 陽性と陰性の胃粘膜所見の特徴胃X線所見. 胃と腸41 (7):1001-1008, 2006.
 
7) 中島滋美, 他:Helicobacter pylori 感染の有無による胃のバリウムX線画像の特徴と診断的価値. 日ヘリコバクター会誌8 (2):18-21, 2007.
 
8) 竹本忠良, 他編:消化管内視鏡診断テキスト 1食道・胃・十二指腸. 文光堂, 東京, 1983.
 
9) 深尾 彰, 他:有効性評価に基づく胃がん検診ガイドライン (普及版). 癌と化療 33 (8):1183-1197, 2006.
Medical*Online
10) 中島滋美:生活習慣病健診の実際 Helicobacter pylori 感染との関連を含め. Helicobacter Res 16 (1):46-51, 2012.
Medical*Online
11) 中島滋美:胃がん検診の現状と展望. 日臨 70 (10):1686-1693, 2012.
Medical*Online
P.108 掲載の参考文献
1) 岡崎和一:内視鏡所見. 消化性潰瘍 (浅香正博編), p87-94 最新医学社, 大阪, 2002.
 
2) 光永 篤:胃潰瘍. 消化管内視鏡診断テキスト(1)第3版 (長廻 紘 編>, p140-177. 文光堂, 東京, 2008.
 
3) 田辺 聡, 他:胃潰瘍の分類. 内視鏡診断のプロセスと疾患別内視鏡像上部消化管第3版 (田尻久雄 監), p374-378. 日本メディカルセンター, 東京, 2011.
 
4) 樋口和秀, 他:胃炎・消化性潰瘍. 必携!消化器内科研修ナビ (樋口和秀監), p60-65. ヴァンメディカル, 東京, 2012.
 
5) 大井田正人:胃潰瘍辺縁粘膜の拡大内視鏡的ならびに病理組織学的観察. 北里医11:575-581, 1981.
 
6) 中村哲也:十二指腸潰瘍. 消化管内視鏡診断テキスト(1)第3版 (長廻 紘 編), p275-287. 文光堂, 東京, 2008
 
7) 川口 淳, 他:十二指腸潰瘍. 内視鏡診断のプロセスと疾患別内視鏡像上部消化管第3版 (田尻久雄 監), p410-413. 日本メディカルセンター, 東京, 2011.
 
8) 樋口和秀, 他:プロスタグランジン. QOUHの評価をめぐって (小林殉三, 他 編) p85-92. 東京医学社, 東京, 1993.
 
9) Arakawa T, et al:Clinical assessment of quality of ulcer healing-a new approach of endoscoplc evaluation. Eur J Gastroenterol Hepatol 5 (suppl 3):S87-S92, 1993.
 
10) Nebiki H, et al:Quality of ulcer healing influences the relapse of gastric ulcer in humans. J Gastrol Hepatol 12:109-114, 1997.
 
11) 内視鏡治療. 消化性潰瘍診療ガイドライン (日本消化器病学会 編), p2-15. 南江堂, 東京, 2009.
 
P.118 掲載の参考文献
1) 消化管エコー研究会:消化管エコーの基本操作 ver 2. ユー・エス・アカデミー, 横浜, 2012.
 
2) 春間 賢 編:消化管超音波診断ビジュアルテキスト. 医学書院,東京, 2004.
 
P.123 掲載の参考文献
1) 市川平三郎, 他:胃潰瘍の良・悪性の鑑別診.胃と腸 8:1163-1172, 1973.
 
2) 佐野量造:胃と腸の臨床病理ノート. 医学書院,東京, 1977.
 

第4章 管理・治療

P.127 掲載の参考文献
1) 間部克裕, 他:内視鏡治療における抗凝固薬, 抗血小板薬の休薬方法. Gstroenterol Endosc 52 (10):2976-2984, 2010.
 
2) 中村孝司, 他:NSAIDS潰瘍の臨床. 日消誌 97 (5):551-559, 2000.
 
3) 太田慎一:胃炎を惹起する薬剤と抑制する薬剤. 21世紀の胃の炎症学 (浅香正博編) pp355-363, メディカルレビュー社, 東京, 2005.
 
4) Kato I, et al:A prospective study of dastric and duodenal ulcer and its reletion to smoking, alcohol and diet Am J Epidemiol 1135:521-530, 1992.
 
5) 和田 薫, 他:消化性潰瘍, 胃切除後の栄養管理. 診断と治療 93 (10):1751-1754, 2005.
 
6) 古田賢司, 他:上部消化管疾患の栄養療法. 日消誌 104 (12):1698-1706, 2007.
Medical*Online
7) 中村丁次:消化によい食事とは. 総合臨 53 (12):33124-3127, 2004.
 
8) 結城美佳, 他:日本人の食生活の変化と胃機能変化. 老年消病 14 (2):101-104, 2002.
Medical*Online
9) Gary D, et al:CIGARETTES, ALCOHOL, COFFEE AND PEPTIC ULCER. N Engl J Med 290 (9):469-473, 1974.
 
10) 中村孝司, 他:消化性潰瘍の経過に及ぼす喫煙, 飲酒ならびにコーヒーの影響に関する検討. 日消誌 80 (12):2493-3503, 1983.
 
11) 加藤元嗣, 他:ラットにおけるエタノール胃粘膜障害の電子内視鏡による経時的観察. Gastroenterol Endosc 35 (7):1581-1587, 1993.
 
12) 並木正義, 他:潰瘍の発生とストレス. 心身医療 3 (3):341-346, 1991.
 
13) 金子 宏, 他:Helicobacter pylori除菌と心身医学的治療により改善をみた胃潰瘍症の1例. Helicobacter Res 4 (2):165-168, 2000.
Medical*Online
P.134 掲載の参考文献
1) EBMに基づく胃潰瘍診療ガイドライン. じほう, 東京, 2007.
 
2) 日本消化器病学会:消化性潰瘍診療ガイドライン. 南江堂, 東京, 2009.
 
3) Salas M, et al:Are proton pump inhibitors the first choice for acutetreatment of gastric ulcers? A meta analysis of randomized clinical trials. BMC Gastroenterol 2:17, 2002.
PubMed
4) Tunis S R, et al:Lansoprazole compared with histamine2-receptor antagonists in healing gastric ulcers:a meta-analysis. Clin Ther 19:743-757, 1997.
 
5) Shin W G, et al:Can rebamipide and proton pump inhibitor combination therapy promote the healing of endoscopic submucosal dissection-induced ulcers? A randomized, prospective, multicenter study. Gastrointest Endosc. 2012 (in press)
 
6) Kobayashi M, et al:Contributing factors to gastric ulcer healing after endoscopic submucosal dissection including the promoting effect of rebamipide. Dig Dis Sci 57:119-126, 2012.
PubMed
7) Fujiwara S, et al:A randomized controlled trial of rebamipide plus rabeprazole for the healing of artificial ulcers after endoscopic submucosal dissection. J Gastroenterol 46:595-602, 2011.
 
8) Kato T, et al:Clinical trial:rebamipide promotes gastric ulcer healing by proton pump inhibitor after endoscopic submucosal dissection-a randomized controlled study. J Gastroenterol 45:285-290, 2010.
PubMed
P.147 掲載の参考文献
1) Ieiri I, et al:Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, CYP2C19m1 in exon 5 and CYP2C19m2 in exon 4, in Japanese subjects. Clin Pharmacol Ther 59:647-653, 1996.
 
2) Sim SC, et al:A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 79:103-113, 2006.
PubMed
3) Sugimoto K, et al:Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population. Br J Clin Pharmacol 65:437-439, 2008.
 
4) Furuta T, et al:CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin Pharmacol Ther 65:552-561, 1999.
PubMed
5) Shirai N, et al:Effects of CYP2C19 geno typic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment Pharmacol Ther 15:1929-1937, 2001.
 
6) Furuta T, et al:Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19. Clin Pharmacol Ther 70:484-492, 2001.
PubMed
7) Nexium Capsule. Interview Form 2011; NEX81F102.
 
8) Lou H Y, et al:Optimal dose regimens of esomeprazole for gastric acid suppression with minimal influence of the CYP2C19 polymorphism. Eur J Clin Pharmacol 65:55-64, 2009.
PubMed
9) Shirai N, et al:Comparison of lansoprazole and famotidine for gastric acid inhibition during the daytime and night-time in different CYP2C19 genotype groups. Aliment Pharmacol Ther 16:837-846, 2002.
PubMed
10) アストラゼネカ株式会社:オメプラール錠インタビューフォーム. 2010.
 
11) アストラゼネカ株式会社:ネキシウムカプセルインタビューフォーム. 2012.
 
12) エーザイ株式会社:パリエット錠インタビューフォーム. 2012.
 
13) 武田薬品工業株式会社:タケプロン インタビューフォーム. 2012.
 
14) Ando T, et al:Endoscopic analysis of gastric ulcer after one week's treatment with omeprazole and rabeprazole in relation to CYP2C19 genotype. Dig Dis Sci 53:933-937, 2008.
 
15) Shirai N, et al:Dual therapy with high doses of rabeprazole and amoxicillin versus triple therapy with rabeprazole, amoxicillin, and metronidazole as a rescue regimen for Helicobacter pylori infection after the standard triple therapy. Eur J Clin Pharmacol 63:743-749, 2007.
PubMed
16) Sugimoto M, et al:Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status. Clin Pharmacol Ther 76:290-301, 2004.
PubMed
17) Shimatani T, et al:Rabeprazole 10mg twice daily is superior to 20mg once daily for night-time gastric acid suppression. Aliment Pharmacol Ther 19:113-122, 2004.
 
18) Furuta T, et al:High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology 50:2274-2278, 2003.
PubMed
19) Miehlke S, et al:A prospective, randomized study of quadruple therapy and high-dose dual therapy for treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. Helicobacter 8:310-319, 2003.
PubMed
20) Furuta T, et al:Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori. Clin Pharmacol Ther 81:521-528, 2007.
PubMed
21) Stedman C A, et al:Review article:comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther 14:963-978, 2000.
PubMed
22) Ho P M, et al:Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 301:937-944, 2009.
PubMed
P.156 掲載の参考文献
1) 蘆田 潔:経口投与不可能な上部消化管出血患者に対するLansoprazole(AG-1749)注射剤の止血効果の検討塩酸ロキサチジンアセタート注射剤との二重盲検比較試験. 薬理と治療 35 (5):503-518, 2007.
 
2) Kamada T, et al:Effect of famotidine on recurrent bleeding after successful endoscopic treatment of bleeding peptic ulcer. Aliment Pharmacol Ther 21 (Suppl 2):73-78, 2005.
 
3) Haruma K, et al:Are proton pump inhibitors really superior to famotidine in Japanese ulcer patients? Hepatogastroenterology 56 (93):1059-1063, 2009.
PubMed
4) Hooper L, et al:The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs:systematic review. BMJ 329:948-958, 2004.
PubMed
5) Yamao J, et al:Assessing the efficacy of famotidine and rebamipide in the treatment of gastric mucosal lesions in patients receiving long-term NSAID therapy (FORCE-famotidine or rebamipide in comparison by endoscopy). J Gastroenterol 41 (12):1178-1185, 2006.
PubMed
6) Taha A S, et al:Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS):a phase III, randomised, double-blind, placebo-controlled trial. Lancet 374:119-125, 2009.
PubMed
7) 三好秋馬:胃潰瘍に対するFamotidineの臨床評価ゲファルナートを対照とした二重盲検法による検討. 診療と新薬 20 (10):2069-2088, 1983.
 
8) Brazer S R, et al:Randomized, double-blind comparison of famotidine with ranitidine in treatment of acute, benign gastric ulcer disease. Community-based study coupled with a patient registry. Dig Dis Sci 34 (7):1047-1052, 1989.
PubMed
9) 三好秋馬:Omeprazoleの胃潰瘍に対する臨床的有用性の検討. 薬理と治療 16:543-561, 1988.
Medical*Online
10) 竹本忠良:胃潰瘍に対するLansoprazole(AG-1749)の臨床的有用性の検討. 臨成人病 21:327-345, 1991.
 
11) 中澤三郎:胃潰瘍に対するE3810の臨床的有用性の検討. 臨評価 21:337-359, 1993.
 
12) Berlin R G, et al:Nocturnal therapy with famotidine for 1 year is effective in preventing relapse of gastric ulcer. Aliment Pharmacol Ther 5 (2):161-171, 1991.
PubMed
13) 三好秋馬:十二指腸潰瘍に対するFamoti-dineの臨床評価ゲファルナートを対照とした二重盲検法による検討. 診療と新薬 20 (10):2089-2108, 1983.
 
14) 松尾 裕:十二指腸潰瘍に対するFRG-8813(Lafutidine)の臨床的有用性の検討-ファモチジンを対照薬とした多施設二重盲検比較試験-. 臨医薬 14:2103-2119, 1998
Medical*Online
15) 三好秋馬:Omeprazoleの十二指腸潰瘍に対する臨床的有用性の検討. 薬理と治療 16:563-582, 1988.
Medical*Online
16) 竹本忠良:十二指腸潰瘍に対するLansoprazole (AG-1749) の臨床的有用性の検討. 臨成人病 21:613-631, 1991.
 
17) 中澤三郎:十二指腸潰瘍に対するE3810の臨床的有用性の検討. 臨評価 21 (3):361-382, 1993.
 
18) Palmer R H, et al:Maintenance therapy of duodenal ulcer with H2-receptor antagonists a meta-analysis. Aliment Pharmacol Ther 4 (3):283-294, 1990.
PubMed
19) 中村正彦:酸分泌抑制薬の作用部位, 特性からみた効果発現に関する考察. Prog Med 22 (3):807-814, 2002.
Medical*Online
20) Lind T, et al:Effect of omeprazole-a gastric proton pump inhibitor-on pentagastrin stimulated acid secretion in man. Gut 24 (4):270-276, 1983.
PubMed
21) Fujisawa T, et al:Helicobacter pylori infection prevents the occurrence of the tolerance phenomenon of histamine H2 receptor antagonists. Aliment Pharmacol Ther 20 (5):559-565, 2004.
PubMed
22) Takahashi M, et al:Reversal of the tolerance phenomenon by the intermittent administration of a histamine H2-receptor antagonist. J Gastroenterol Hepatol 25 (9):1493-1497, 2010.
PubMed
23) Peghini P L:Ranitidine controls nocturnal gastric acid breakthrough on omeprazole:a controlled study in normal subjects. Gastroenterology 115 (6):1335-1339, 1998
PubMed
24) 岡信秀治:Functional dyspepsiaに対するNizatidineの効果 体外式超音波法による胃十二指腸運動の評価. 臨と研76 (10):2049-2052, 1999.
 
25) 吉田憲正:ファモチジンの塩酸-アスピリン惹起性胃粘膜傷害に対する阻止効果. Prog Med 22 (3):826-830, 2002,
Medical*Online
P.164 掲載の参考文献
1) 日本消化器病学会編:H. pylori除菌治療. 消化性潰瘍診療ガイドライン, p26-56. 南江堂, 東京, 2009.
 
2) 土岐真朗, 他:抗潰瘍薬の使い方-H. pylori潰瘍. 診断と治療 97:1150-1156, 2009.
 
3) 胃潰瘍ガイドラインの適用と評価に関する研究班:胃潰瘍の基礎知識. EBMに基づく胃潰瘍診療ガイドライン第2版,p9-11. じほう, 東京, 2007.
 
4) Miwa H, et al:Recurrent peptic ulcers in patients following successful Helicobacter pylori eradication:a multicenter study of 4940 patients. Helicobacter 9:9-16, 2004.
PubMed
5) 日本ヘリコバクター学会ガイドライン作成委員会:日本ヘリコバクター学会 "H. pylori感染の診断と治療のガイドライン 2009改訂版". 日ヘリコバクター会誌 10:104-128, 2009.
 
6) 小林寅哲, 他:わが国における薬剤耐性 Helicobacter pyloriの現状. 第14回日本ヘリコバクター学会抄録集 115, 2008.
 
7) Higuchi K, et al:Efficacy and safety of Helicobacter pyrori eradication therapy with omeprazole, amoxicillin and high-and low-dose clarithromycin in Japanese patients. Clin Drug Invest 26:403-414, 2006.
 
8) 徳永健吾, 他:Helicobacter pylori 除菌判定における13C-尿素呼気試験の有用性と問題点. 日消誌 102:176-182, 2005.
Medical*Online
P.170 掲載の参考文献
1) Taha A S, et al:Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal anti-inflammatory drugs. N Engl J Med 334:435-439, 1996.
 
2) Saggioro A, et al:Misoprostol prevents NSAID-induced gastroduodenal lesions in patients with osteoarthritis and rheumatoid arthritis. Ital J Gastroenterol 23:119-123, 1991.
PubMed
3) Bianchi Porro G, et al:Prevention of gastroduodenal damage with omeprazole in patients receiving continuous NSAIDs treatment. A double blind placebo controlled study. Ital J Gastroenterol Hepatol 30:43-47, 1998.
PubMed
4) Graham D Y, et al:NSAID-Associated Gastric Ulcer Prevention Study Group. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs:results of adouble-blind, randomized, multicenter, active-and placebo-controlled study of misoprostol vs lansoprazole. Arch Intern Med 162 (2):169-175, 2002.
 
5) Sugano K, et al:Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term low-dose aspirin therapy:results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial. J Gastroenterol 46:724-735, 2011.
 
6) Antman E M, et al:Use of nonsteroidal anti-inflammatory drugs:an update for clinicians:a scientific statement from the American Heart Association. Circulation 115:1634-1642, 2007.
PubMed
7) Hooper L, et al:The effectiveness of five strategies fbr the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs:systematic review. BMJ 329 (7472):948, 2004.
 
8) White W B, et al:Risk of cardiovascular events in patients receiving celecoxib:a meta-analysis of randomized clinical trials. Am J Cardiol 99 (1):91-98, 2007.
PubMed
9) Garcia Rodriguez L A:Nonsteroidal anti-inflammatory drugs, Ulcers and risk:a collaborative meta-analysis. Semin Arthritis Rheum 26 (6 Suppl 1):16-20, 1997.
 
10) Chan F K, et al:Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet 350:975-979, 1997.
PubMed
11) de Leest HT, et al:Eradication of Helicobacter pylori does not reduce the incidence of gastroduodenal ulcers in patients on long-term NSAID treatment:double-blind, randomized, placebo-controlled trial. Helicobacter 12 (5):477-485, 2007.
 
12) Vergara M, et al:Meta-analysis:role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther 21 (12):1411-1418, 2005.
PubMed
13) Jaszewski R, et al:Treatment of nons-teroidal anti-inflammatory drug-induced gastric ulcers with misoprostol. A double-blind multicenter study. Dig Dis Sci 37:1820-1824, 1992.
 
14) 石川茂直:低用量アスピリンによる重篤な胃・十二指腸障害の特徴と予防. 消化器科 47 (5):471-478, 2008.
 
15) Agrawal N M, et al:Superiority of lanso-prazole vs ranitidine in healing nons-teroidal anti-inflammatory drug-associated gastric ulcers:results of a double-blind, randomized, multicenter study. NSAID-Associated Gastric Ulcer Study Group. Arch Intern Med 160 (10):1455-1461, 2000.
 
16) Campbell D R, et al:Effect of H. pylori status on gastric ulcer healing in patients continuing nonsteroidal anti-inflammatory therapy and receiving treatment with lansoprazole or ranitidine. Am J Gastroenterol 97 (9):2208-2214, 2002.
PubMed
17) Chan F K, et al:Does eradication of Helicobacter pylori impair healing of nonsteroidal anti-inflammatory drug associated bleeding peptic ulcers? A prospective randomized study, Aliment Pharmacol Ther 12:1201-1205, 1998.
PubMed
18) Hawkey C J, et al:Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs:HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention. Lancet 352:1016-1021, 1998.
PubMed
P.178 掲載の参考文献
1) Donnelly M T, et al:Low-dose misoprostol for the prevention of low-dose aspirin-induced gastroduodenal injury. Aliment Pharmacol Ther 14:529-534, 2000.
PubMed
2) Ono S, et al:Preliminary trial of rebamipide for prevention of low-dose aspirin-induced gastric injury in healthy subjects:a randomized, double-blind, placebo-controlled, cross-over study. J Clin Biochem Nutr 45:248-253, 2009.
PubMed
3) Taha A S, et al:Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS):a phase III, randomised, double-blind, placebo-controlled trial. Lancet 374:119-125, 2009.
PubMed
4) Yeomans N, et al:Efficacy of esomeprazole (20mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am J Gastroenterol 103:2465-2473, 2008.
 
5) Ng FH, et a Esomeprazole compared:with famotidine in the prevention of upper gastrointestinal bleeding in patients with acute coronary syndrome or myocardial infarction. Am J Gastroenterol 107:389-396, 2012.
PubMed
6) Douglas I J, et al:Clopidogrel and interaction with proton pump inhibitors:comparison between cohort and within person study designs. BMJ 345:e4388, 2012.
PubMed
7) Ng F H, et al:Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. Gastroenterology 138:82-88, 2010.
PubMed
8) Sugano K, et al:Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term low-dose aspirin therapy:results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial. J Gastroenterol 46:724-735, 2011.
 
9) Sanuki T, et al:Rabeprazole reduces the recurrence risk of peptic ulcers associated with low-dose aspirin in patients with cardiovascular or cerebrovascular disease:a prospective randomized active-controlled trial. J Gastroenterol (2012).
PubMed
10) Chan F K, et al:Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 344:967-973, 2001.
PubMed
11) Lai K C, et al:Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 346:2033-2038, 2002.
 
12) Sung J J, et al:Continuation of low-dose aspirin therapy in pepticulcer bleeding:a randomized trial. Ann Intern Med 152:1-9, 2010.
 
P.185 掲載の参考文献
1) 竹下公谷, 他:上部消化管出血の病体と内視鏡止血法の進歩. 消内視鏡 13:1709-1717, 2001.
 
2) Kohler B, et al:Upper GI-bleeding:value and consequences of emergency endoscopy and endoscopic treatment. Hepatogastroenterology 38:198-200, 1991.
PubMed
3) Laine L, et al:Bleeding peptic ulcer. N Engl J Med 331:717-727, 1994.
PubMed
4) Sacs H S, et al:Endoscopic hemostasis An effective therapy for bleeding peptic ulcers. JAMA 264:494-499, 1990.
 
5) Shimoda R, et al:Evaluation of endoscopic hemostasis with metallic hemoclips for bleeding gastric ulcer:comparison with endoscopic injection of absolute ethanol in a prospective, randomized study. Am J Gastroenterol 98:2198-2202, 2003
 
6) 蜂巣忠:上部消化管出血に対する経内視鏡的クリップ止血法 (改良型クリップの開発と経験). Gastroenterol Endosc 27:276-281, 1985.
 
7) 平尾雅紀, 他:上部消化管出血に対する止血術-HSE局注法のコツ. 消内視鏡 11:1309-1312, 1999.
 
8) 矢作直作:Flexナイフ. 消化器内視鏡治療における高周波発生装置の使い方と注意点 (矢作直作 編). p9-102. 日本メディカルセンター, 東京, 2005.
 

第5章 ガイドライン

P.202 掲載の参考文献
1) EBMに基づく胃潰瘍診療ガイドライン. じほう, 東京, 2003.
 
2) 日本消化器病学会編:消化性潰瘍診療ガイドライン. 南江堂, 東京, 2009.
 
3) Minds診療ガイドライン選定部会 監 福井次矢, 他 編:Minds診療ガイドライン作成の手引き2007. 医学書院, 東京, 2007.
 

第6章 診療のトピックス

P.211 掲載の参考文献
1) Silverstein F E, et al:Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-infammatory drugs for osteoarthritis and rheumatoid arthritis:the CLASS study:A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284:1247-1255, 2000
 
2) Solomon S D, et al:Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352:1071-1080, 2005.
 
3) Arber N et al:Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 355:885-895, 2006.
PubMed
4) Cardiovascular and cerebrovascular events in the randomized controlled Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT). PLoS Clin Trials 1:e33, 2006.
 
5) Goldstein J L, et al:Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol 3:133-141, 2005.
PubMed
6) Hasegawa M, et al:Prevention of Celecoxib Induced Gastrointestinal Events by Concomitant Therapy with Rebamipide, Gastro-Protective Drug. Arthritis Rheumatism 63, pp777 (supplement), 2011.
 
7) Kobayashi K, et al:Prophylactic effects ranitidme, a H2 receptor antagonist, on gastric and duodenal lesions induced by nonsteroidal anti-infiammatory agents. J Adult Dis 20:253-264, 1990.
 
8) Horiki N, et al:Prevention of celecoxib induced gastrointestinal mucosal damage by concomitant therapy with rebamipide, gastro-protective drug. Digestive Diswase Week pp Su1767, 2012.
 
9) Singh G, et al:Celecoxib versus naproxen and diclofenac in osteoarthritis patients:SUCCESS-I Study. Am J Med 119:255-266, 2006.
PubMed
10) Bombardier C, et al:Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343:1520-1528, 2000.
 
11) Lisse J R, et al:Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis:a randomized, controlled trial. Ann Intern Med 139:539-546, 2003.
PubMed
12) Delaney J A, et al:Drug drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding. CMAJ 177:347-351, 2007.
PubMed
13) Hsiang K W, et al:Incidence and possible risk factors for clinical upper gastrointestinal events in patients taking selective cyclooxygenase-2 inhibitors:A prospective, observational, cohort study in Taiwan. Clin Ther 32:1294-1303, 2010.
PubMed
P.219 掲載の参考文献
1) Yeomans N et al:Efficacy of esomeprazole (20mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am J Gastroenterol 103:1-9, 2008.
 
2) Endo H, et al:Quantitative analysis of low-dose aspirin-associated small bowel injury using a capsule endoscopy scoring index. Dig Endosc 23:56-61, 2011.
PubMed
3) Strate LL, et al:Use of aspirin or nonsterodal anti-inflammatory drugs increases risk for diverticulitis and diverticular bleeding. Gastrotenterology 140:1427-1433, 2011.
 
4) Schoen R T, et al:Mechanisms of nonsteroidal anti-inflammatory drug-induced gastric damage. Am J Med 86 (4):449-458, 1989.
PubMed
5) Bjarnason I, et al:Determinants of the short-term gastric damage caused by NSAIDs in man. Aliment Pharmacol Ther 26:95-106, 2007.
PubMed
6) Nishino M, et al:Relationship Between Low-Dose Aspirin-induced Gastric Mucosal Injury and Intragastric pH in Healthy Volunteers Dig Dis Sci 55:1627-1636, 2010.
PubMed
7) Lai K C, et al:Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 346:2033-2038, 2002.
 
8) Taha A S, et al:Famotidine for the preventsion of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS):a phase III, randomised, double-blind, placebo controlled trial. Lancet 374:119-125, 2009.
 
9) Higuchi K, et al:Prevention of NSAID-induced Small Intestinal Mucosal Injury:Prophylactic Potential of Lansoprazole. J Clin Biochem Nutr 45:125-130, 2009.
PubMed
10) Mizukami K, et al:Aspirin-induced small bowel injuries and the preventive effect of rebamipide. World J Gastroenterol 17 (46):5117-5122, 2011.
PubMed
11) Endo H, et al:Characteristics of sman bowel injury in symptomatic chronic low-dose aspirin users:the experience of two medicalcenters in capsule endoscopy. J Gastroenterol 44:544-549, 2009.
 
12) Shiotani A, et al:Randomized, double-blind, pilot study of geranylgeranylacetone versus placebo in patients taking low-dose enteric-coated aspirin. Low-dose aspirininduced small bowel damage. Scand J Gastroenterol 45:292-298, 2010.
 
13) Niwa Y, et al:Geranylgeranylacetone protects against diclofenac-induced gastric and small intestinal mucosal injuries in healthy subjects:a prospective randomized placebo-controlled double-blind cross-over study. Digestion 80 (4):260-266, 2009.
PubMed
14) Yoda Y, et al:Prevention by lansoprazole, a proton pump inhibitor, of indomethacininduced small intestinal ulcerationin rats through induction of heme oxygenase-1. J Physiol Pharmacol 61 (3):287-294, 2010.
 
15) Wallace J L, et al:Proton pump inhibitors exacerbate NSAIDs induced sall intestine injury by induced dysbiosis. Gastroenterology 141:1314-1322, 2011.
 
16) Fujimori S, et al:Rebamipide has the potential to reduce the intensity of NSAIDinduced small intestinal injury:adouble-blind, randomized, controlled trial evaluated by capsule endoscopy. J Gastroenterol 46 (1):57-64, 2011.
 
17) Mizukami K, et al:Aspirin-induced small bowel injuries and the preventive effect of rebamipide. World J Gastroenterol 17 (46):5117-5122, 2011.
PubMed
18) Niwa Y, et al:Efficacy of rebamipide for diclofenac-induced small-intestinal mucosal injuries in healthy subjects:a prospective, randomized, double-blinded, placebo-controlled, cross-over study. J Gastroenterol 43:270-276, 2008.
PubMed
19) Suzuki T, et al:Prophylactic Effect of Rebamipide on Aspirin-Induced Gastric Lesionsand Disruption of Tight Junctional Protein Zonula Occludens-1 Distribution. J Pharmacol Sci 106:469-477, 2008.
 
20) Tanaka K, et al:Genetic evidence for a protective role of heat shock factor I against irritant-induced gastric lesions. Mol Pharmacol 71 (4):985-993, 2007.
 
21) Kamei K, et al:Prophylactic effect of irsogladine maleate against indomethacin-induced small intestinal lesions in rats. Dig Dis Sci 53 (10):2657-2666, 2008.
PubMed
22) Endo H, et al:Efficacy of Lactobacillus casei treatment on small bowel injury in chronic low-dose aspirin users:a pilot randomized controlled study. J Gastroenterol 46:894-905, 2011.
PubMed
23) Fujimoro S, et al:Prevention of nonsteroidal anti-inflammatory drug-induced small-intestinal injury by prostaglandin:a pilot randomized controlled trial evaluated by capsule endoscopy. Gastrointest Endosc 69:1339-1346, 2009.
 
24) Watanabe T, et al:Small Bowel Injury by Low-Dose Enteric-coated Aspirin and Treatment With Misoprostol:A Pilot Study. Clin Gastroenterol Hepatol 6:1279-1282, 2008.
PubMed
P.227 掲載の参考文献
1) Vonkeman H E, et al:Incremental cost effectiveness of proton pump inhibitors for the prevention of non-steroidal anti-inflamatory drug ulcers:a pharmacoeconomic analysis linked to a case-control study. Arthritis Res Ther 10 (6):R144, 2008.
 
2) Cameron C, et al:Cost-utility analysis of proton pump inhibitors and other gastro protective agents for prevention of gastrointestinal complications in elderly patients taking nonselective nonsteroidal anti-inflammatory agents. Aliment Pharmacol Ther 31 (12):1354-1364, 2010.
PubMed
P.234 掲載の参考文献
1) Smallwood R A, et al:Safety of acid-suppressing drugs.Dig Dis Sci 40(2 Suppl):63S-80S,1995.
 
2) 鈴木 剛, 他:Lansoprazoleにより誘発された急性免疫性溶血性貧血. 臨血 37:1389-1394, 1996.
 
3) 石井邦英, 他:オメプラゾールによる劇症肝炎の1剖検例. 肝臓 39:877,1998.
 
4) 宮田聡子, 他:オメプラゾールが原因と考えられた TEN 型薬疹. 西日皮 58:574-577, 1996.
 
5) Schonhofer P S:Intravenous omeprazole and blindness.Lancet 343:665,1994.
 
6) 河野通盛, 他:プロトンポンプ阻害剤により視力障害をきたした2症例. 日消誌 97:575-579,2000.
Medical*Online
7) Myers R P, et al:Acute interstitial nephritis due to omeprazole.Am J Gastfoenterol 96:3428-3431,2001.
 
8) Umeno J, et al:Linear mucosal defect may be characteristic of lansoprazole-associated collagenous colitis.Gastrointest Endosc 67:1185-1191,2008.
PubMed
9) Carlsson E, et al:Pharmacology and toxicology of omeprazole-with special reference to the effects on gastric mucosa.Scand J Gastroenterol Suppl 118:31-38,1986.
 
10) Kahrilas P J,et al:American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease.Gastroenterology 135:1392-1413,2008.
PubMed
11) Kuipers E J, et al:Atrophic gastritis and Helicobocter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication.N Engl J Med 334:1018-1022,1996.
PubMed
12) Leonard J,et al:Systematic review of the risk of enteric infection in patients taking acid suppression.Am J Gastroenterol 102:2047-2056,2007.
PubMed
13) Laheij R J, et al:Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 292:1955-1960,2004.
PubMed
14) Eom CS, et al:Use of acid-suppressive drugs and risk of fracture:a meta-analysis of observational studies. Ann Fam Med 9:257-267,2011.
PubMed
P.243 掲載の参考文献
1) 日本消化器病学会 編:消化性潰瘍診療ガイドライン. p92-113. 南江堂, 東京, 2009.
 
2) Tryba M:Sucralfate versus antacids or H2-antagonists for stress ulcer prophylaxis:a meta-analysis on efficacy and pneumonia rate. Crit Care Med 19:942-949, 1991.
 
3) Di Mario F, et al:Short-term treatment of gastric ulcer. A metaranalytical evaluation of blind trials. Dig Dis Sci 41 (6):1108-1131, 1996.
PubMed
4) Hawkey C J, et al:Omeprazole compared with misoprostol for ulcers associated with nonsteroidal anti-inflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 338 (11):727-734, 1998
 
5) Higuchi K, et al:Sofalcone, a gastroprotective drug, promotes gastric ulcer healing following eradication therapy for Helicobacter pylori:a randomized controlled comparative trial with cimetidine, an H2-receptor antagonist. J Gastroenterol Hepatol 25 (Suppl 1):S155-160, 2010.
PubMed
6) Terano A, et al:Rebamipide a gastro-protective and anti-inflammatory drug, promotes gastric ulcer healing following eradication therapy for Helicobacter pylori in a Japanese population:a randomized, double-blind, placebo controlled trial J Gastroenterol 42:690-693, 2007.
 
7) Song K H, et al:Healing effects of rebamipide and omeprazole in Helicobacter pylori-positive gastric ulcer patients after eradication therapy:a randomized double-blind, multinational, multi-institutional comparative study. Digestion 84 (3):221-229, 2011.
PubMed
8) Hiraishi H, et al:Clinical tria:irsogladine maleate, a mucosal protective drug, accelerates gastric ulcer healing after treatment for eradication of Helicobacter pylori infection-the results of a multicentre, doubleblind, randomized clinical trial (IMPACT study). Aliment Pharmacol Ther 31 (8):824-833, 2010.
 
9) Murakami K, et al:Comparison of the efficacy of irsogladine maleate and famotidine for the healing of gastric ulcers after Helicobacter pylori eradication therapy:a randomized, controlled, prospective study. Scand J Gastroenterol 46 (3):287-292, 2011.
PubMed
10) Hooper L, et al:The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs:systematic review. BMJ 329:948-958, 2004.
PubMed
11) Rostom A, et al:Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev 2002:CD002296.
PubMed
12) Park S H, et al:Comparison of Preventionof NSAID-induced Gastrointestinal Complications by Rebamipide and Misoprostol:A Randomized, Multicenter, Controlled Trial-STORM STUDY. J Clin Biochem Nutr 40 (2):148-155, 2007.
 
13) Yamao J, et al:Assessing the efficacy of famotidine and rebamipide in the treatment of gastric mucosal lesions in patients receiving long-term NSAID therapy (FORCE-famotidine or rebamipide in comparison by endoscopy). J Gastroenterol 41 (12):1178-1185, 2006.
PubMed
14) Tsumura H, et al:Prescription of nonsteroidal anti-inflammatory drugs and coprescribed drugs for mucosal protection:analysis of the present status based on questionnaires obtained from orthopedists in Japan. Intern Med 46 (13):927-931, 2007.
 
15) Kato T, et al:Clinical trial:rebamipide promotes gastric ulcer healing by proton pump inhibitor after endoscopic submucosal dissection-a randomized controlled study. J Gastroenterol 45 (3):285-290, 2010.
PubMed
16) Fujiwara S, et al:A randomized controlled trial of rebamipide plus rabeprazole for the healing of artificial ulcers after endoscopic submucosal dissection. J Gastroenterol 46 (5):595-602, 2011.
 
17) Shin W G, et al:Can rebamipide and proton pump inhibitor combination therapy promote the healing of endoscopic submucosal dissection-induced ulcers? A randomized, prospective, multicenter study. Gastrointest Endosc 75 (4):739-747, 2012.
PubMed
18) Wallace J L, et al:Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. J Gastroenterol 141 (4):1314-1322, 2011.
 
19) Mizukami K, et al:Aspirin-induced small bowel injuries and the preventive effect of rebamipide. World J Gastroenterol 17 (46):5117-5122, 2011.
PubMed
20) Fujimori S, et al:Rebamipide has the potential to reduce the intensity of NSAID-induced small intestinal injury:adouble-blind, randomized, controlled trial evaluated by capsule endoscopy. J Gastroenterol 46 (1):57-64, 2011.
 
21) Niwa Y, et al:Efficacy of rebamipide for diclofenac-induced small-intestinal mucosal injuries in healthy subjects:a prospective, randomized, double-blinded, placebo-controlled, cross-over study. J Gastroenterol 43 (4):270-276, 2008.
PubMed

書評

最近チェックした商品履歴

Loading...